JPH09309813A - Preparation for external use for skin - Google Patents
Preparation for external use for skinInfo
- Publication number
- JPH09309813A JPH09309813A JP15016896A JP15016896A JPH09309813A JP H09309813 A JPH09309813 A JP H09309813A JP 15016896 A JP15016896 A JP 15016896A JP 15016896 A JP15016896 A JP 15016896A JP H09309813 A JPH09309813 A JP H09309813A
- Authority
- JP
- Japan
- Prior art keywords
- preparation
- tocopherol
- comparative example
- salt
- external preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 22
- 239000002736 nonionic surfactant Substances 0.000 claims abstract description 7
- QXNVGIXVLWOKEQ-UHFFFAOYSA-N Disodium Chemical class [Na][Na] QXNVGIXVLWOKEQ-UHFFFAOYSA-N 0.000 claims abstract description 3
- 159000000000 sodium salts Chemical class 0.000 claims abstract description 3
- 150000003839 salts Chemical class 0.000 claims description 12
- -1 α-tocopherol phosphate ester Chemical class 0.000 claims description 10
- 239000002280 amphoteric surfactant Substances 0.000 claims description 4
- 238000002156 mixing Methods 0.000 claims description 3
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 abstract description 15
- 229960000984 tocofersolan Drugs 0.000 abstract description 8
- 229940087168 alpha tocopherol Drugs 0.000 abstract description 7
- 239000002076 α-tocopherol Substances 0.000 abstract description 7
- 235000004835 α-tocopherol Nutrition 0.000 abstract description 7
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 abstract description 5
- 150000002148 esters Chemical class 0.000 abstract description 5
- 229930003427 Vitamin E Natural products 0.000 abstract description 2
- 230000003078 antioxidant effect Effects 0.000 abstract description 2
- 239000007864 aqueous solution Substances 0.000 abstract description 2
- 230000001804 emulsifying effect Effects 0.000 abstract description 2
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 abstract description 2
- 230000003381 solubilizing effect Effects 0.000 abstract description 2
- 229940046009 vitamin E Drugs 0.000 abstract description 2
- 235000019165 vitamin E Nutrition 0.000 abstract description 2
- 239000011709 vitamin E Substances 0.000 abstract description 2
- 239000003963 antioxidant agent Substances 0.000 abstract 1
- 235000006708 antioxidants Nutrition 0.000 abstract 1
- 239000004615 ingredient Substances 0.000 abstract 1
- 239000000243 solution Substances 0.000 abstract 1
- 230000000052 comparative effect Effects 0.000 description 24
- 239000000839 emulsion Substances 0.000 description 16
- 239000006210 lotion Substances 0.000 description 12
- 238000004519 manufacturing process Methods 0.000 description 12
- 238000003756 stirring Methods 0.000 description 12
- 230000007794 irritation Effects 0.000 description 11
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 7
- 239000003921 oil Substances 0.000 description 4
- 235000019198 oils Nutrition 0.000 description 4
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 239000006071 cream Substances 0.000 description 3
- 238000005191 phase separation Methods 0.000 description 3
- XDOFQFKRPWOURC-UHFFFAOYSA-N 16-methylheptadecanoic acid Chemical compound CC(C)CCCCCCCCCCCCCCC(O)=O XDOFQFKRPWOURC-UHFFFAOYSA-N 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- JUIUXBHZFNHITF-IEOSBIPESA-N [(2r)-2,5,7,8-tetramethyl-2-[(4r,8r)-4,8,12-trimethyltridecyl]-3,4-dihydrochromen-6-yl] dihydrogen phosphate Chemical compound OP(=O)(O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C JUIUXBHZFNHITF-IEOSBIPESA-N 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 238000013329 compounding Methods 0.000 description 2
- 239000002537 cosmetic Substances 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 2
- 239000010452 phosphate Substances 0.000 description 2
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N squalane Chemical compound CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 2
- 150000003772 α-tocopherols Chemical class 0.000 description 2
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 1
- BJDAUCLANVMIOB-UHFFFAOYSA-N (3-decanoyloxy-2,2-dimethylpropyl) decanoate Chemical compound CCCCCCCCCC(=O)OCC(C)(C)COC(=O)CCCCCCCCC BJDAUCLANVMIOB-UHFFFAOYSA-N 0.000 description 1
- OYHQOLUKZRVURQ-NTGFUMLPSA-N (9Z,12Z)-9,10,12,13-tetratritiooctadeca-9,12-dienoic acid Chemical compound C(CCCCCCC\C(=C(/C\C(=C(/CCCCC)\[3H])\[3H])\[3H])\[3H])(=O)O OYHQOLUKZRVURQ-NTGFUMLPSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- IMHQFVGHBDXALM-UHFFFAOYSA-N 2,2-diethylhexanoic acid Chemical compound CCCCC(CC)(CC)C(O)=O IMHQFVGHBDXALM-UHFFFAOYSA-N 0.000 description 1
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 1
- BGRXBNZMPMGLQI-UHFFFAOYSA-N 2-octyldodecyl tetradecanoate Chemical compound CCCCCCCCCCCCCC(=O)OCC(CCCCCCCC)CCCCCCCCCC BGRXBNZMPMGLQI-UHFFFAOYSA-N 0.000 description 1
- UIVPNOBLHXUKDX-UHFFFAOYSA-N 3,5,5-trimethylhexyl 3,5,5-trimethylhexanoate Chemical compound CC(C)(C)CC(C)CCOC(=O)CC(C)CC(C)(C)C UIVPNOBLHXUKDX-UHFFFAOYSA-N 0.000 description 1
- 239000004166 Lanolin Substances 0.000 description 1
- 241000772415 Neovison vison Species 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 235000021302 avocado oil Nutrition 0.000 description 1
- 239000008163 avocado oil Substances 0.000 description 1
- 235000013871 bee wax Nutrition 0.000 description 1
- 235000015278 beef Nutrition 0.000 description 1
- 229940092738 beeswax Drugs 0.000 description 1
- 239000012166 beeswax Substances 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 229960000541 cetyl alcohol Drugs 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 239000004205 dimethyl polysiloxane Substances 0.000 description 1
- 235000013870 dimethyl polysiloxane Nutrition 0.000 description 1
- KCIDZIIHRGYJAE-YGFYJFDDSA-L dipotassium;[(2r,3r,4s,5r,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl] phosphate Chemical class [K+].[K+].OC[C@H]1O[C@H](OP([O-])([O-])=O)[C@H](O)[C@@H](O)[C@H]1O KCIDZIIHRGYJAE-YGFYJFDDSA-L 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000003912 environmental pollution Methods 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 229940100554 isononyl isononanoate Drugs 0.000 description 1
- 229940119170 jojoba wax Drugs 0.000 description 1
- 235000019388 lanolin Nutrition 0.000 description 1
- 229940039717 lanolin Drugs 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 230000003020 moisturizing effect Effects 0.000 description 1
- JXTPJDDICSTXJX-UHFFFAOYSA-N n-Triacontane Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCC JXTPJDDICSTXJX-UHFFFAOYSA-N 0.000 description 1
- GOQYKNQRPGWPLP-UHFFFAOYSA-N n-heptadecyl alcohol Natural products CCCCCCCCCCCCCCCCCO GOQYKNQRPGWPLP-UHFFFAOYSA-N 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 229940073665 octyldodecyl myristate Drugs 0.000 description 1
- 229940056211 paraffin Drugs 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 238000011076 safety test Methods 0.000 description 1
- 229920002545 silicone oil Polymers 0.000 description 1
- 229940032094 squalane Drugs 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 150000005846 sugar alcohols Polymers 0.000 description 1
- 239000003760 tallow Substances 0.000 description 1
- TUNFSRHWOTWDNC-HKGQFRNVSA-N tetradecanoic acid Chemical compound CCCCCCCCCCCCC[14C](O)=O TUNFSRHWOTWDNC-HKGQFRNVSA-N 0.000 description 1
- 229930003799 tocopherol Natural products 0.000 description 1
- 239000011732 tocopherol Substances 0.000 description 1
- 235000010384 tocopherol Nutrition 0.000 description 1
- 229960001295 tocopherol Drugs 0.000 description 1
- 150000003611 tocopherol derivatives Chemical class 0.000 description 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
- 229940099259 vaseline Drugs 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
Landscapes
- Cosmetics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
【発明の詳細な説明】
【0001】
【産業上の利用分野】 本発明は、α−トコフェロール
リン酸エステルを配合することを特徴とする皮膚外用剤
に関する。
【0002】
【従来の技術】 α−トコフェロールはビタミンEの一
種であり高い抗酸化能、血行促進作用等の薬理作用を有
しており、古くから医薬品、化粧品、飼料等に配合され
ている。また、今後もその利用価値は大きくなると思わ
れる。
【0003】
【本発明が解決しようとする課題】 しかし従来、α−
トコフェロールおよび/またはα−トコフェロール誘導
体は油溶性で水溶液やエマルジョンに均一に配合するこ
とは困難であった。また、医薬品、化粧品等において可
溶化状態またはエマルジョンとして調製する場合、一般
的に非イオン性界面活性剤を併用すれば均一に分散させ
ることも可能であるが、非イオン性界面活性剤のなかに
は刺激性の高いものや環境汚染を引き起こすものもあ
り、安全性の面等からも好ましくないと考えられる。一
方、α−トコフェロールリン酸エステルおよび/または
その塩類は、ある程度の水溶性を有するものの、均一に
分散させるためには特開昭59−44375に開示され
ているように、非イオン性界面活性剤を併用しなければ
ならない為に、α−トコフェロールおよび/またはα−
トコフェロール誘導体と同様の問題を持っている。本発
明はこのような課題を解決して、安定性および安全性の
高い組成物を提供することを目的とする。
【0004】
【問題点を解決するための手段】 本発明者らは、これ
らの諸問題に対し解決すべく手段を検討した結果、α−
トコフェロールリン酸エステルおよび/またはその塩類
が有用な可溶化能および乳化能を有することを見いだ
し、本発明を完成するに到った。すなわち、本発明は油
溶性成分を同一系に配合することによりα−トコフェロ
ールリン酸エステルおよび/またはその塩類および油溶
性成分を可溶化状態または乳化状態として均一に分散さ
せることを可能としたものである。また、レシチンのよ
うな安全性の高い両性界面活性剤を用いて、α−トコフ
ェロールリン酸エステルおよび/またはその塩類を併用
した皮膚外用剤を調製すると安全性の高い製剤を得るこ
とができる。本発明で用いられるα−トコフェロールリ
ン酸エステルおよび/またはその塩類は何でも良いが、
好ましくはモノエステル、塩はナトリウム塩、ジナトリ
ウム塩、カリウム塩、ジカリウム塩等の金属塩および/
またはモノエタノールアミン、トリエタノールアミン等
の有機塩でよい。α−トコフェロールリン酸エステルお
よび/またはその塩類の配合量は0.01〜20重量%が好ま
しく、さらに好ましくは0.05〜10重量%である。本発明
で用いられる油溶性成分は皮膚外用剤として使用できる
ものであれば何でも良いが、α−トコフェロールおよび
/またはα−トコフェロール誘導体等の脂溶性ビタミン
をはじめとして、アボカド油、ひまし油、牛脂、ミンク
油等の油脂類、ラノリン、ミツロウ、ホホバ油等のロウ
類、流動パラフィン、スクワラン、ワセリン、パラフィ
ン等の炭化水素類、ミリスチン酸、ステアリン酸、イソ
ステアリン酸、リノール酸等の脂肪酸類、エタノール、
セタノール、ステアリルアルコール、コレステロール等
のアルコール類、プロピレングリコール、ブチレングリ
コール、グリセリン、ポリエチレングリコール等の多価
アルコール類、2エチルヘキサン酸トリグリセリド、イ
ソノナン酸イソノニル、ジカプリン酸ネオペンチルグリ
コール、ミリスチン酸オクチルドデシル等のエステル
類、ジメチルポリシロキサン、メチルフェニルポリシロ
キサン、揮発性環状シリコーン等のシリコーンオイル等
が挙げられる。油溶性成分の配合量は0.01〜99重量%の
広範囲において適応が可能である。本発明で用いられる
両性界面活性剤は何でも良いが、好ましくはリン酸エス
テル型、カルボン酸型等であり、さらに好ましくは水素
添加リン脂質である。両性界面活性剤の配合量は0.1〜3
0重量%が好ましく、さらに好ましくは0.5〜5.0重量%
である。また、本発明の皮膚外用剤には、本発明の効果
を損なわない範囲で、一般に皮膚外用剤に用いられる成
分を配合することができる。
【0005】
【実施例】本発明を実施例により詳細に説明するが、本
発明は実施例に限定されるものではない。実施例中の配
合量は重量%である。また、安全性試験については実験
動物を用いクローズドパッチ法にて実施した。
(以下余白)(比較例1および実施例1の製造方法)1〜6を均一に分
散溶解し、撹拌しながら7に添加し目的のローション1
を得る。(結果)実施例1において得られたローション
1は透明性に優れ、低刺激性および良好な経時安定性を
示した。これに対し、比較例1においては均一に溶解ま
たは分散することができず、透明性に優れたローション
を得ることはできなかった。
(以下余白)
(比較例2および実施例2の製造方法)1〜5を均一に分
散溶解し、撹拌しながら6に添加し目的のローション2
を得る。(結果)実施例2において得られたローション
2は透明性に優れ、低刺激性および良好な経時安定性を
示した。これに対し、比較例2においては均一に溶解ま
たは分散することができず、油滴の浮遊が確認され、透
明性に優れたローションを得ることはできなかった。
(以下余白)(比較例3および実施例3の製造方法)1〜6を均一に分
散溶解し、撹拌しながら7に添加し目的のローション3
を得る。(結果)実施例3において得られたローション
3は透明性に優れ、低刺激性および良好な経時安定性を
示した。これに対し、比較例3においては均一に溶解ま
たは分散することができず、透明性に優れたローション
を得ることはできなかった。
(以下余白)
(比較例4および実施例4の製造方法)1〜5を均一に分
散溶解し、撹拌しながら6に添加し目的のローション4
を得る。(結果)比較例4において得られたノンエタノ
ールタイプのローション4は透明性に優れ、良好な経時
安定性を示した。また、実施例3において得られたノン
エタノールタイプのローション4も非イオン性界面活性
剤を配合していないにも関わらず、優れた透明性および
良好な経時安定性を示し、比較例4に比して低刺激性を
示した。
(以下余白)(比較例5および実施例5の製造方法)1〜3を均一に分
散溶解し、撹拌しながら4を添加し目的のゲル状外用剤
1を得る。
(結果)実施例5において得られたゲル状外用剤1は透
明ゲル状の外観を有し、低刺激性および良好な経時安定
性を示した。これに対し、比較例5においてはゲル形成
がなされなかった。
(以下余白)
(比較例6および実施例6の製造方法)1〜3を均一に分
散溶解し、撹拌しながら4を添加し目的のゲル状外用剤
2を得る。
(結果)実施例6において得られたゲル状外用剤2は透
明ゲル状の外観を有し、低刺激性および良好な経時安定
性を示した。これに対し、比較例6においてはゲル形成
がなされなかった。
(以下余白)
(比較例7および実施例7の製造方法)1〜4を均一に分
散溶解し、撹拌しながら5を添加し目的のゲル状外用剤
3を得る。
(結果)比較例7において得られたゲル状外用剤3は透
明ゲル状の外観を有し良好な経時安定性を示した。これ
に対し、実施例7において得られたゲル状外用剤も非イ
オン性界面活性剤を配合していないにも関わらず透明ゲ
ル状の外観を有し、良好な経時安定性を示し、さらに比
較例7より良好な安全性を示した。
(以下余白)
(比較例8および実施例8の製造方法)1〜4を均一に分
散溶解し、撹拌しながら5を添加し目的の乳剤1を得
る。
(結果)実施例8において得られた乳剤1はさっぱりと
した使用感触を有し、低刺激性および良好な経時安定性
を示した。これに対し、比較例8においてはエマルジョ
ンが形成されず、乳剤を得ることが出来なかった。
(以下余白)
(比較例9および実施例9の製造方法)1〜4を均一に分
散溶解し、撹拌しながら5を添加し目的の乳剤2を得
る。
(結果)実施例9において得られた乳剤2はさっぱりと
した使用感触を有し、低刺激性および良好な経時安定性
を示した。これに対し、比較例9においては乳剤は得ら
れるが数日後に相分離が観察され、良好な経時安定性を
得ることは出来なかった。
(以下余白)(比較例10および実施例10の製造方法)1〜4を均一に分
散溶解し、撹拌しながら5を添加し目的の乳剤3を得
る。
(結果)実施例10において得られた乳剤3はさっぱりと
した使用感触を有し、低刺激性および良好な経時安定性
を示した。これに対し、比較例10においては乳剤は得ら
れるが数日後に相分離が観察され、良好な経時安定性を
得ることは出来なかった。
(以下余白)
(比較例11および実施例11の製造方法)1〜4を均一に分
散溶解し、撹拌しながら5を添加し目的の乳剤4を得
る。
(結果)実施例11において得られた乳剤4はさっぱりと
した使用感触を有し、低刺激性および良好な経時安定性
を示した。これに対し、比較例11においては乳剤は得ら
れるが数日後に相分離が観察され、良好な経時安定性を
得ることは出来なかった。
(以下余白)(比較例12および実施例12の製造方法)1〜5を均一に分
散溶解し、撹拌しながら均一に分散溶解した6〜10を添
加し目的のクリームを得る。
(結果)実施例12において得られたクリームはしっとり
とした使用感触を有し、低刺激性および良好な経時安定
性を示した。これに対し、比較例12においてはエマルジ
ョンが形成されず、クリームを得ることが出来なかっ
た。Description: BACKGROUND OF THE INVENTION 1. Field of the Invention The present invention relates to an external preparation for skin characterized by containing α-tocopherol phosphate ester. [0002] α-Tocopherol is a kind of vitamin E and has a high antioxidative ability and a pharmacological action such as a blood circulation promoting action, and has been compounded for a long time in medicines, cosmetics, feeds and the like. In addition, its utility value is expected to increase in the future. However, conventionally, α-
Tocopherol and / or α-tocopherol derivatives are oil-soluble and it was difficult to uniformly mix them in an aqueous solution or emulsion. In addition, when prepared as a solubilized state or an emulsion in pharmaceuticals, cosmetics, etc., it is generally possible to disperse evenly by using a nonionic surfactant together, but some nonionic surfactants are irritating. Some of them are highly prone to cause environmental pollution, and are considered unfavorable in terms of safety. On the other hand, the α-tocopherol phosphate and / or its salts have a certain degree of water solubility, but in order to disperse them uniformly, as disclosed in JP-A-59-44375, a nonionic surfactant is used. .Alpha.-tocopherol and / or .alpha.-
It has the same problem as the tocopherol derivative. An object of the present invention is to solve such problems and provide a composition having high stability and safety. Means for Solving the Problems As a result of studying means for solving these problems, the present inventors have found that α-
The inventors have found that tocopherol phosphate ester and / or its salts have useful solubilizing ability and emulsifying ability, and completed the present invention. That is, the present invention makes it possible to uniformly disperse the α-tocopherol phosphate ester and / or its salts and the oil-soluble component in a solubilized state or an emulsified state by blending the oil-soluble component in the same system. is there. Further, a highly safe preparation can be obtained by preparing a skin external preparation using a highly safe amphoteric surfactant such as lecithin in combination with α-tocopherol phosphate and / or a salt thereof. The α-tocopherol phosphate ester and / or its salt used in the present invention may be any,
Preferably, the monoester or salt is a metal salt such as sodium salt, disodium salt, potassium salt or dipotassium salt and / or
Alternatively, an organic salt such as monoethanolamine or triethanolamine may be used. The blending amount of the α-tocopherol phosphate ester and / or its salt is preferably 0.01 to 20% by weight, more preferably 0.05 to 10% by weight. The oil-soluble component used in the present invention may be anything that can be used as a skin external preparation, including fat-soluble vitamins such as α-tocopherol and / or α-tocopherol derivative, avocado oil, castor oil, beef tallow, mink. Fats and oils such as oil, waxes such as lanolin, beeswax, jojoba oil, hydrocarbons such as liquid paraffin, squalane, vaseline and paraffin, fatty acids such as myristic acid, stearic acid, isostearic acid and linoleic acid, ethanol,
Alcohols such as cetanol, stearyl alcohol and cholesterol, polyhydric alcohols such as propylene glycol, butylene glycol, glycerin and polyethylene glycol, diethylhexanoic acid triglyceride, isononyl isononanoate, neopentyl glycol dicaprate, octyldodecyl myristate, etc. Examples thereof include esters, dimethylpolysiloxane, methylphenylpolysiloxane, and silicone oil such as volatile cyclic silicone. The compounding amount of the oil-soluble component can be applied in a wide range of 0.01 to 99% by weight. The amphoteric surfactant used in the present invention may be any, but is preferably a phosphate ester type, a carboxylic acid type or the like, and more preferably a hydrogenated phospholipid. The amount of amphoteric surfactant is 0.1 to 3
0% by weight is preferred, more preferably 0.5-5.0% by weight
It is. Further, the external preparation for skin of the present invention may contain components generally used in the external preparation for skin, as long as the effects of the present invention are not impaired. The present invention will be described in detail with reference to examples, but the present invention is not limited to the examples. The compounding amount in the examples is% by weight. The safety test was conducted by the closed patch method using experimental animals. (Below margin) (Production Method of Comparative Example 1 and Example 1) 1 to 6 are uniformly dispersed and dissolved, and added to 7 with stirring to obtain the desired lotion 1
Get. (Results) Lotion 1 obtained in Example 1 had excellent transparency, low irritation, and good stability over time. On the other hand, in Comparative Example 1, it was not possible to uniformly dissolve or disperse, and it was not possible to obtain a lotion having excellent transparency. (Below margin) (Manufacturing method of Comparative Example 2 and Example 2) 1 to 5 are uniformly dispersed and dissolved, and added to 6 while stirring to obtain the intended lotion 2
Get. (Results) Lotion 2 obtained in Example 2 had excellent transparency, low irritation and good stability over time. On the other hand, in Comparative Example 2, it was not possible to uniformly dissolve or disperse the oil particles, and it was confirmed that oil droplets floated, and it was not possible to obtain a lotion having excellent transparency. (Below margin) (Manufacturing method of Comparative Example 3 and Example 3) 1 to 6 are uniformly dispersed and dissolved, and added to 7 with stirring to obtain the desired lotion 3.
Get. (Results) Lotion 3 obtained in Example 3 had excellent transparency, low irritation and good stability over time. On the other hand, in Comparative Example 3, it was not possible to uniformly dissolve or disperse, and it was not possible to obtain a lotion having excellent transparency. (Below margin) (Manufacturing method of Comparative Example 4 and Example 4) 1 to 5 are uniformly dispersed and dissolved, and added to 6 with stirring to obtain the intended lotion 4
Get. (Results) The non-ethanol type lotion 4 obtained in Comparative Example 4 was excellent in transparency and showed good stability over time. In addition, the non-ethanol type lotion 4 obtained in Example 3 also showed excellent transparency and good stability over time, even though it did not contain a nonionic surfactant. And showed low irritation. (Below margin) (Production method of Comparative Example 5 and Example 5) 1 to 3 are uniformly dispersed and dissolved, and 4 is added with stirring to obtain the intended gel external preparation 1. (Results) The gel-type external preparation 1 obtained in Example 5 had a transparent gel-like appearance, and showed low irritation and good stability over time. On the other hand, in Comparative Example 5, gel formation was not performed. (Below margin) (Production Method of Comparative Example 6 and Example 6) 1 to 3 are uniformly dispersed and dissolved, and 4 is added with stirring to obtain the desired gel external preparation 2. (Results) The gel-type external preparation 2 obtained in Example 6 had a transparent gel-like appearance, and exhibited low irritation and good stability over time. On the other hand, in Comparative Example 6, gel formation was not performed. (Below margin) (Manufacturing method of Comparative Example 7 and Example 7) 1 to 4 are uniformly dispersed and dissolved, and 5 is added with stirring to obtain the intended gel external preparation 3. (Results) The gel external preparation 3 obtained in Comparative Example 7 had a transparent gel appearance and exhibited good stability over time. On the other hand, the gel external preparation obtained in Example 7 also had a transparent gel-like appearance even though it did not contain a nonionic surfactant, and showed good stability over time. It showed better safety than Example 7. (Below margin) (Production method of Comparative Example 8 and Example 8) 1 to 4 are uniformly dispersed and dissolved, and 5 is added with stirring to obtain a target emulsion 1. (Results) Emulsion 1 obtained in Example 8 had a refreshing feel on use, showed low irritation and good stability over time. On the other hand, in Comparative Example 8, an emulsion was not formed and an emulsion could not be obtained. (Below margin) (Production method of Comparative Example 9 and Example 9) 1 to 4 are uniformly dispersed and dissolved, and 5 is added with stirring to obtain a target emulsion 2. (Results) Emulsion 2 obtained in Example 9 had a refreshing feeling to use, showed low irritation and good stability over time. On the other hand, in Comparative Example 9, although an emulsion was obtained, phase separation was observed after several days, and good stability over time could not be obtained. (Below margin) (Production Method of Comparative Example 10 and Example 10) 1 to 4 are uniformly dispersed and dissolved, and 5 is added with stirring to obtain a target emulsion 3. (Results) Emulsion 3 obtained in Example 10 had a refreshing feeling to use, showed low irritation and good stability over time. On the other hand, in Comparative Example 10, although an emulsion was obtained, phase separation was observed after several days, and good stability over time could not be obtained. (Below margin) (Production Method of Comparative Example 11 and Example 11) 1 to 4 are uniformly dispersed and dissolved, and 5 is added with stirring to obtain the objective Emulsion 4. (Results) Emulsion 4 obtained in Example 11 had a refreshing feel on use, showed low irritation and good stability over time. On the other hand, in Comparative Example 11, although an emulsion was obtained, phase separation was observed after several days, and good stability over time could not be obtained. (Below margin) (Production method of Comparative Example 12 and Example 12) 1 to 5 are uniformly dispersed and dissolved, and 6 to 10 that are uniformly dispersed and dissolved while stirring are added to obtain a target cream. (Results) The cream obtained in Example 12 had a moisturizing feeling to use, showed low irritation and good stability over time. On the other hand, in Comparative Example 12, no emulsion was formed and a cream could not be obtained.
───────────────────────────────────────────────────── フロントページの続き (72)発明者 中田 悟 名古屋市西区鳥見町2丁目7番地 日本メ ナード化粧品株式会社総合研究所内 ────────────────────────────────────────────────── ─── Continuation of front page (72) Inventor Satoru Nakata 2-7 Torimicho, Nishi-ku, Nagoya-shi Nard Cosmetics Co., Ltd.
Claims (1)
び/またはその塩を配合し、かつ非イオン性界面活性剤
を配合しないことを特徴とする皮膚外用剤。 【請求項2】 両性界面活性剤を配合することを特徴と
する 【請求項1】の皮膚外用剤。 【請求項3】 α−トコフェロールリン酸エステルおよ
び/またはその塩の配合量が0.01〜10%であることを特
徴とする 【請求項1】の皮膚外用剤。 【請求項4】 α−トコフェロールリン酸エステルおよ
び/またはその塩がナトリウム塩および/またはジナト
リウム塩であることを特徴とする 【請求項1】の皮膚外用剤。Claims: 1. An external preparation for skin, which comprises an α-tocopherol phosphate ester and / or a salt thereof and does not include a nonionic surfactant. 2. An external preparation for skin according to claim 1, which further comprises an amphoteric surfactant. 3. The external preparation for skin according to claim 1, wherein the blending amount of the α-tocopherol phosphate ester and / or its salt is 0.01 to 10%. 4. The external preparation for skin according to claim 1, wherein the α-tocopherol phosphate ester and / or its salt is a sodium salt and / or a disodium salt.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP15016896A JPH09309813A (en) | 1996-05-22 | 1996-05-22 | Preparation for external use for skin |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP15016896A JPH09309813A (en) | 1996-05-22 | 1996-05-22 | Preparation for external use for skin |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JPH09309813A true JPH09309813A (en) | 1997-12-02 |
Family
ID=15490998
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP15016896A Pending JPH09309813A (en) | 1996-05-22 | 1996-05-22 | Preparation for external use for skin |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPH09309813A (en) |
Cited By (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2002040034A1 (en) * | 2000-11-14 | 2002-05-23 | Vital Health Sciences Pty Ltd. | Complexes of phosphate derivatives |
| WO2002040033A1 (en) * | 2000-11-14 | 2002-05-23 | Vital Health Sciences Pty Ltd | Formulation containing phosphate derivatives of electron transfer agents |
| WO2003094882A1 (en) * | 2002-05-09 | 2003-11-20 | Showa Denko K.K. | Skin whitening external preparation |
| JP2004538308A (en) * | 2001-07-27 | 2004-12-24 | バイタル ヘルス サイエンシズ プロプライアタリー リミティド | Skin treatment using phosphoric acid derivatives of electron transfer agents |
| JP2006169143A (en) * | 2004-12-14 | 2006-06-29 | Nippon Menaade Keshohin Kk | Skin external composition |
| JP2007238497A (en) * | 2006-03-08 | 2007-09-20 | Nippon Menaade Keshohin Kk | Compounded powdery material and make-up cosmetic containing the same |
| JP2013107871A (en) * | 2011-10-26 | 2013-06-06 | Fancl Corp | Liquid crystal composition |
| JP2014141432A (en) * | 2013-01-23 | 2014-08-07 | Showa Denko Kk | Skin external preparation and production method thereof |
| JP2014141431A (en) * | 2013-01-23 | 2014-08-07 | Showa Denko Kk | Skin external preparation |
| US10071030B2 (en) | 2010-02-05 | 2018-09-11 | Phosphagenics Limited | Carrier comprising non-neutralised tocopheryl phosphate |
| US10188670B2 (en) | 2011-03-15 | 2019-01-29 | Phosphagenics Limited | Composition |
| US10973761B2 (en) | 2015-12-09 | 2021-04-13 | Phosphagenics Limited | Pharmaceutical formulation |
| US11753435B2 (en) | 2016-12-21 | 2023-09-12 | Avecho Biotechnology Limited | Process |
-
1996
- 1996-05-22 JP JP15016896A patent/JPH09309813A/en active Pending
Cited By (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN100396287C (en) * | 2000-11-14 | 2008-06-25 | 生命健康科学有限公司 | Formulations containing phosphate derivatives of electron transfer agents |
| JP2004513183A (en) * | 2000-11-14 | 2004-04-30 | バイタル ヘルス サイエンシズ プロプライアタリー リミティド | Complex of phosphoric acid derivative |
| JP2004516251A (en) * | 2000-11-14 | 2004-06-03 | バイタル ヘルス サイエンシズ プロプライアタリー リミティド | Formulation containing a phosphate derivative of an electron transfer agent |
| WO2002040033A1 (en) * | 2000-11-14 | 2002-05-23 | Vital Health Sciences Pty Ltd | Formulation containing phosphate derivatives of electron transfer agents |
| WO2002040034A1 (en) * | 2000-11-14 | 2002-05-23 | Vital Health Sciences Pty Ltd. | Complexes of phosphate derivatives |
| JP2004538308A (en) * | 2001-07-27 | 2004-12-24 | バイタル ヘルス サイエンシズ プロプライアタリー リミティド | Skin treatment using phosphoric acid derivatives of electron transfer agents |
| WO2003094882A1 (en) * | 2002-05-09 | 2003-11-20 | Showa Denko K.K. | Skin whitening external preparation |
| JP2006169143A (en) * | 2004-12-14 | 2006-06-29 | Nippon Menaade Keshohin Kk | Skin external composition |
| JP2007238497A (en) * | 2006-03-08 | 2007-09-20 | Nippon Menaade Keshohin Kk | Compounded powdery material and make-up cosmetic containing the same |
| US10071030B2 (en) | 2010-02-05 | 2018-09-11 | Phosphagenics Limited | Carrier comprising non-neutralised tocopheryl phosphate |
| US10188670B2 (en) | 2011-03-15 | 2019-01-29 | Phosphagenics Limited | Composition |
| JP2013107871A (en) * | 2011-10-26 | 2013-06-06 | Fancl Corp | Liquid crystal composition |
| JP2014141431A (en) * | 2013-01-23 | 2014-08-07 | Showa Denko Kk | Skin external preparation |
| JP2014141432A (en) * | 2013-01-23 | 2014-08-07 | Showa Denko Kk | Skin external preparation and production method thereof |
| US10973761B2 (en) | 2015-12-09 | 2021-04-13 | Phosphagenics Limited | Pharmaceutical formulation |
| US11753435B2 (en) | 2016-12-21 | 2023-09-12 | Avecho Biotechnology Limited | Process |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP4527530B2 (en) | Vesicle dispersion and cosmetics containing the same | |
| JP5148127B2 (en) | Nanoemulsion, process for producing the same, and cosmetic and dermatological composition containing the same | |
| JP3489703B2 (en) | Fine emulsion composition | |
| KR20100052479A (en) | Oil-in-water emulsion composition and method for producing the same | |
| EP0084341B2 (en) | Emulsion-type composition for external use | |
| JPH09309813A (en) | Preparation for external use for skin | |
| EP1414389A1 (en) | Oily thickened gel-like composition, emulsified composition using the composition, and preparation method thereof | |
| JPS6245336A (en) | Emulsified composition | |
| JP2983311B2 (en) | External preparation for skin | |
| JP4756493B2 (en) | Topical skin preparation | |
| JPH0533926B2 (en) | ||
| JP2004307414A (en) | W/o/w emulsion skin care preparation for external use and method for producing the same | |
| JPS58183938A (en) | Emulsified composition | |
| JP3799276B2 (en) | Gel composition and emulsion composition | |
| JPS6186940A (en) | Oil in water type emulsion composition | |
| JPH09151112A (en) | Microemulsion composition | |
| JPS61204109A (en) | Emulsion-type composition for external use | |
| JP2854767B2 (en) | Thickening gelling agent | |
| JP2729304B2 (en) | Oil-in-water emulsion composition | |
| JP2004346039A (en) | Emulsified composition | |
| JP2748962B2 (en) | Hydrophilic gel composition and oil-in-water emulsion composition | |
| JPH10316523A (en) | Oil-in-water type emilsified composition | |
| JPS6230546A (en) | Polybasic acid type bio-surfactant emulsified composition | |
| JP2002020229A (en) | Emulsified composition | |
| JP2003212751A (en) | Gel composition and oil-in-water (o/w) composition |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A977 | Report on retrieval |
Effective date: 20040909 Free format text: JAPANESE INTERMEDIATE CODE: A971007 |
|
| A131 | Notification of reasons for refusal |
Effective date: 20041012 Free format text: JAPANESE INTERMEDIATE CODE: A131 |
|
| A711 | Notification of change in applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A712 Effective date: 20041116 |
|
| A521 | Written amendment |
Effective date: 20041206 Free format text: JAPANESE INTERMEDIATE CODE: A523 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20051108 |